natgillin/translations-raw huggingface dataset:
The solution for injection is used for the treatment of pain and inflammation associated with orthopaedic (bone) or soft tissue surgery.
Raztopina za injiciranje se uporablja za zdravljenje bolečine in vnetja po ortopedskih operativnih posegih (na kosteh) ali operativnih posegih na mehkih tkivih.
The tablets are given once a day at the same time every day, at a dose of 1 mg per kilogramme body weight with a range of 1-2 mg/ kg.
Tablete se dajejo enkrat dnevno ob istem času vsak dan, pri čemer je odmerek 1 mg na kilogram telesne mase v območju 1– 2 mg/ kg.
Treatment in cats is limited to six days.
Zdravljenje pri mačkah je omejeno na šest dni.
Dogs should be treated for as long as is needed.
Pse je treba zdraviti toliko časa, kot je potrebno.
The solution for injection is given to cats or dogs around 30 minutes before the start of the operation at a dose of 2 mg/ kg.
Raztopina za injiciranje se daje mačkam ali psom približno 30 minut pred začetkom operativnega posega, pri čemer je odmerek 2 mg/ kg.
The active substance in Onsior, robenacoxib, belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
Zdravilna učinkovina v zdravilu Onsior, robenakoksib, spada v skupino zdravil, imenovanih nesteroidna antirevmatična zdravila (NSAID).
It works by blocking an enzyme called cyclo-oxygenase 2 (COX-2).
Deluje z zaviranjem encima, imenovanega ciklooksigenaza 2 (COX- 2).
This enzyme is involved in producing substances called prostaglandins, which are involved in pain and inflammation.
Ta encim je vključen v proizvajanje snovi, imenovanih prostaglandini, ki so vključene pri bolečini in vnetju.
By blocking the production of prostaglandins, robenacoxib reduces the pain and inflammation caused by musculoskeletal disorders, surgery or osteoarthritis.
Z zaviranjem proizvajanja prostaglandinov robenakoksib zmanjšuje bolečino in vnetje, ki ju povzročijo mišičnoskeletna obolenja, operativni poseg ali osteoartritis.
Onsior has been studied in laboratory animals, as well as ‘ clinical studies ’ in cats and dogs that were treated in veterinary practices and clinics across Europe.
Zdravilo Onsior je bilo raziskano na laboratorijskih živalih ter tudi v „ kliničnih študijah “ na mačkah in psih, ki so bili zdravljeni v veterinarskih ambulantah in klinikah po Evropi.
In the clinical studies, Onsior was compared with other veterinary medicines containing NSAIDs (ketoprofen, meloxicam or carprofen).
V kliničnih raziskavah so zdravilo Onsior primerjali z ostalimi veterinarskimi zdravili, ki vsebujejo nesteroidna antirevmatična zdravila (ketoprofen, meloksikam ali karprofen).
The tablets were studied over five to six days in cats with acute musculoskeletal disorders and for up to one year in dogs with osteoarthritis.
Tablete so raziskovali pet do šest dni na mačkah z akutnimi mišičnoskeletnimi obolenji in do enega leta na psih z osteoartritisom.
The animals received the tablets once or twice a day.
Živali so prejele tablete enkrat ali dvakrat dnevno.
The effectiveness was determined based on examinations by a veterinarian and assessments by the animal’ s owner.
Učinkovitost je bila določena na podlagi presoje veterinarja in ocene lastnika živali.
The solution for injection was studied in cats and dogs undergoing surgery.
Raztopina za injiciranje je bila raziskana na mačkah in psih, na katerih je bil opravljen operativni poseg.
Pain was assessed by the veterinarian for up to 24 hours after treatment, based on the animal’ s behaviour and responses to touching the inflamed area or moving the affected joint.
Veterinar je ocenil bolečino do 24 ur po zdravljenju na podlagi vedenja živali in njenih odzivov na dotik vnetega predela ali premikanje prizadetega sklepa.
Onsior tablets given once a day reduced pain and improved mobility in both cats and dogs.
Tablete Onsior, ki so jih živali prejele enkrat dnevno, so zmanjšale bolečino in izboljšale gibljivost tako pri mačkah kot tudi psih.
Onsior was as effective as the comparator NSAIDs.
Zdravilo Onsior je bilo tako učinkovito kot primerjalna nesteroidna antirevmatična zdravila.
After the end of the operation, sufficient pain control was seen up to 24 hours in dogs and up to 22 hours in cats.
Po koncu operativnega posega je bil opažena zadostna omejitev bolečine do 24 ur pri psih in do 22 ur pri mačkah.
The most common side effects of the tablets and solution for injection are mild and transient effects on the stomach and gut, seen as vomiting, soft faeces and diarrhoea.
Neželeni učinki zdravila Onsior so podobni tistim, ki so jih opazili pri drugih nesteroidnih antirevmatičnih zdravilih Najpogostejši neželeni učinki tablet in raztopine za injiciranje so blagi in prehodni učinki v želodcu in črevesju, opaženi kot bruhanje, mehko blato in driska.
In 1% to 10% of dogs, there was an increase in liver enzymes after long-term treatment with the tablets.
Pri 1% do 10% psov je bil opažen porast jetrnih encimov po dolgotrajnem zdravljenju s tabletami.
Onsior tablets must not be used in dogs or cats with existing problems affecting the stomach and gut, such as stomach ulcers or bleeding, or in dogs with liver problems.
Tablete Onsior se ne smejo uporabljati pri psih in mačkah z obstoječimi težavami, ki prizadenejo želodec in črevesje, kot so razjede na želodcu ali krvavitev, ali pri psih s težavami z jetri.
Care should be taken when treating cats or dogs with known heart or kidney problems and cats with liver problems.
Pri zdravljenju mačk in psov z znanimi težavami s srcem ali ledvicami in mačk s težavami z jetri je potrebna pazljivost.
Onsior must not be used with other NSAIDs or with glucocorticosteroids.
Zdravilo Onsior se ne sme uporabljati skupaj z drugimi nesteroidnimi antirevmatičnimi zdravili ali glukokortikosteroidi.
Wash your hands after you have administered the medicine to a dog or cat.
Ko ste dali zdravilo psu ali mački, si umijte roke.
In case of accidental ingestion of the tablets, in particular by small children, or self-injection with the solution for injection, seek medical advice immediately and show the Package Leaflet or the label to the doctor.
V primeru nenamernega zaužitja tablet, še posebno pri majhnih otrocih, ali samoinjiciranja raztopine za injiciranje se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali ovojnino.
For pregnant women, particularly those in the later stages of pregnancy, accidental ingestion or self-injection of Onsior might be dangerous for the unborn child.
Nenamerno zaužitje ali samoinjiciranje zdravila Onsior je lahko pri nosečnicah, še posebno v poznejši nosečnosti, nevarno za nerojenega otroka.
Page 2/ 3
Stran 2/ 3
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Onsior exceed the risks for the treatment of dogs and cats in the approved indications and recommended that Onsior should be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Onsior pri zdravljenju psov in mačk z odobrenimi indikacijami večje od z njim povezanih tveganj, in priporočil odobritev dovoljenja za promet z zdravilom Onsior.
The benefit-risk balance may be found in module 6 of this EPAR.
Razmerje med koristmi in tveganji se nahaja v modulu 6 tega evropskega javnega poročila o oceni zdravila (EPAR).
The European Commission granted a marketing authorisation valid throughout the European Union for Onsior to Novartis Animal Health UK Ltd on 16.12.2008.
Evropska komisija je dovoljenje za promet z zdravilom Onsior, veljavno po vsej Evropski uniji, odobrila družbi Novartis Animal Health UK Ltd dne 16. 12. 2008.
This summary was last updated on 16.12.2008.
Ta povzetek je bil nazadnje posodobljen 16. 12. 2008.
Pharmaceutical Form
Ciljne živalske vrste
Target species
Pot uporabe
6 mg
Onsior 6 mg
Blister (Alu/ Alu)
Pretisni omot (Aluminijasto/ aluminijasti)
Pharmaceutical
Izmišljeno Jakost ime
Package size
Ciljne živalske vrste
Withdrawal
Pot uporabe
20 mg
Onsior 20 mg
Blister (Alu/ Alu)
Pretisni omot
Not applicable
smiselna
For a full list of excipients see section 6.1.
Za celoten seznam pomožnih
Round, beige to brown tablets with imprints “ NA ” on one side and “ AK” on the other side.
Okrogle, bež do rjave barve tablete z vtisnjenima oznakama » NA « na eni in » AK « na drugi strani.
See section 4.7 (pregnancy and lactation).
Glejte poglavje 4. 7 (brejost in laktacija).
Special precautions for use in animals The safety of the veterinary medicinal product has not been established in cats weighing less than 2.5 kg or under 4 months of age.
Posebni previdnostni ukrepi za uporabo pri živalih Varnost zdravila ni bila dokazana za mačke lažje od 2, 5 kg telesne mase oziroma mlajše od 4 mesecev.
If use cannot be avoided, these cats require careful monitoring.
Če se uporabi v takih primerih ne morete izogniti, potrebujejo mačke strog veterinarski nadzor.
2 Special precautions to be taken by the person administering the veterinary medicinal product to animals Wash hands after use of the veterinary medicinal product.
2 Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo za uporabo v veterinarski medicini Po uporabi zdravila si umijte roke.
For pregnant women, particularly near term pregnant women, prolonged dermal exposure increases the risk for premature closure of the ductus arteriosus in the foetus.
Dolgotrajnejše izpostavljanje kože pri nosečnicah, zlasti blizu porodnega termina, poveča tveganje za predčasno zaprtje duktusa arteriozusa pri plodu.
4.6 Adverse reactions (frequency and seriousness)*
4. 6 Neželeni učinki (pogostost in resnost) *
* The frequency of possible adverse effects is defined using the following convention: very common (affects more than 1 animal in 10) common (affects 1 to 10 animals in 100) uncommon (affects 1 to 10 animals in 1,000) rare (affects 1 to 10 animals in 10,000) very rare (affects less than 1 animals in 10,000) not known (frequency cannot be estimated from the available data).
* Frekvenca možnih neželenih učinkov je opredeljena z naslednjimi dogovori: zelo pogosto (prizadene več kot 1 žival od 10) pogosto (prizadene 1 do 10 živali od 100) manj pogosto (prizadene 1 do 10 živali od 1000) redko (prizadene 1 do 10 živali od 10000) zelo redko (prizadene manj kot 1 žival od 10000) neznano (frekvence ni možno ugotoviti iz razpoložljivih podatkov).
Pre-treatment with other anti- inflammatory medicines may result in additional or increased adverse effects and, accordingly a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior.
Predhodno zdravljenje z drugimi antirevmatičnimi zdravili lahko povzroči dodatne ali povečane neželene učinke, zato je potrebno pred pričetkom zdravljenja z Onsiorjem zagotoviti vsaj 24- urno obdobje brez zdravljenja s takšnimi snovmi.
Concomitant treatment with medicines displaying action on renal flow, e. g. diuretics or angiotensin converting enzyme (ACE) inhibitors, should be subject to clinical monitoring.
Sočasno zdravljenje z zdravili, ki vplivajo na ledvični pretok, npr. diuretiki ali inhibitorji angiotenzin konvertaze (ACE), mora biti pod strogim veterinarskim nadzorom.
Onsior tablets are easy to administer and well accepted by most cats.
Onsior tablete je lahko uporabljati in jih večina mačk dobro sprejme.
The tablets should not be divided or broken.
Tablet ne smete deliti ali prelomiti.
The recommended dose of robenacoxib is 1 mg/ kg body weight with a range 1-2.4 mg/ kg.
Priporočen odmerek robenakoksiba je 1 mg/ kg telesne mase v območju 1- 2, 4 mg/ kg.
Administer once daily at the same time every day, for up to 6 days according to the table below.
Dajte enkrat dnevno, vsak dan ob istem času, do največ 6 dni glede na spodnjo tabelo.
Body weight (kg) 2.5 to < 6 6 to < 12
Telesna masa (kg) 2, 5 do < 6 6 do < 12
Number of tablets 1 tablet 2 tablets
Število tablet 1 tableta 2 tableti
In healthy young cats aged 7-8 months, oral robenacoxib administered at high overdoses (4, 12, or 20 mg/ kg/ day for 6 weeks) did not produce any signs of toxicity, including no evidence of any gastrointestinal, kidney or liver toxicity and no effect on bleeding time.
Pri zdravih mačkah, starih 7- 8 mesecev se po 6 tednih prevelikih peroralnih odmerkov robenakoksiba (4, 12 ali 20 mg/ kg/ dan) niso pojavili znaki toksičnosti na prebavilih, ledvicah ali jetrih ter ni bilo vpliva na čas krvavitve.
As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised cats.
Pri občutljivih ali ogroženih mačkah je lahko prevelik odmerek, kot pri drugih NSAID, toksičen za prebavila, ledvica ali jetra.
Anti-inflammatory and anti-rheumatic products, non-steroids, coxibs.
Protivnetna in antirevmatična zdravila, nesteroidi, koksibi.
Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID) of the coxib class.
Robenakoksib je nesteroidno antirevmatično zdravilo (NSAID), iz skupine koksibov.
It is a potent and selective inhibitor of the cyclooxygenase 2 enzyme (COX-2).
Je učinkovit in selektiven zaviralec encima ciklooksigenaze 2 (COX- 2).
COX-1 is the constitutive form of the enzyme and has protective functions, e. g. in the gastrointestinal tract and kidneys.
COX- 1 je konstitutivna oblika encima, ki ima zaščitno funkcijo, npr. v prebavnem traktu in ledvicah.
COX-2 is the inducible form of the enzyme which is responsible for the production of mediators including PGE2 which induce pain, inflammation or fever.
COX- 2 je inducibilna oblika encima, ki je odgovorna za sintezo mediatorjev, vključno s PGE2, ki inducirajo bolečino, vnetje ali povišano telesno temperaturo.
In the in vitro whole blood assay in cats, robenacoxib was approximately 500 fold selective for COX-2 (IC50 0.058 µM) as compared to COX-1 (IC50 28.9 µM).
Raziskave celokupne krvi pri mačkah in vitro so pokazale, da deluje robenakoksib približno 500 krat bolj selektivno na COX- 2 (IC50 0, 058 µM) kot na COX- 1 (IC50 28, 9 µM).
1-2 mg/ kg robenacoxib tablets produced a marked inhibition of COX-2 activity in cats and had no effect on COX-1 activity.
Pri mačkah so tablete robenakoksiba v odmerkih 1- 2 mg/ kg povzročile vidno inhibicijo COX- 2 aktivnosti, medtem ko na COX- 1 aktivnost niso vplivale.
In an inflammation model in cats, robenacoxib injection had analgesic, anti-inflammatory and anti-pyretic actions and a rapid onset of action (0.5 h).
Pri vnetnem modelu na mačkah je injiciranje robenakoksiba učinkovalo hitro (0, 5 h) protibolečinsko, protivnetno in antipiretično.
In clinical trials in cats, robenacoxib tablets reduced pain and inflammation associated with musculoskeletal disorders.
V kliničnih poskusih na mačkah so tablete robenakoksiba zmanjšale bolečino in vnetje v povezavi z mišičnoskeletnimi obolenji.
Absorption After oral administration of robenacoxib tablets at approximately 2 mg/ kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 h, a Cmax of 1159 ng/ ml and an AUC of 1337 ng. h/ ml.
Absorpcija Po peroralnem vnosu tablet robenakoksiba v priporočenem odmerku 2 mg/ kg telesne mase brez hrane je bila maksimalna koncentracija v plazmi (Cmax 1159 ng/ ml) hitro dosežena (Tmax 0, 5 h), površina pod krivuljo koncentracije v plazmi v odvisnosti od časa (AUC) je znašala 1337 ng. h/ ml.
Co-administration of robenacoxib tablets with one third of the daily food ration produced no change in Tmax (0.5 h), Cmax (1201 ng/ ml) or AUC (1383 ng. h/ ml).
Vnos tablet robenakoksiba s tretjino dnevnega obroka hrane ni povzročil bistvenih sprememb pri Tmax (0, 5 h), Cmax (1201 ng/ ml) ali AUC (1383 ng. h/ ml).
Co-administration of robenacoxib tablets with the entire daily food ration produced no delay in Tmax (0.5 h), but a lower Cmax (691 ng/ ml) and a slightly lower AUC (1069 ng. h/ ml).
Pri vnosu tablet robenakoksiba s celotnim dnevnim obrokom hrane sta bili, ob hitri absorbciji (Tmax 0, 5 h), maksimalna koncentracija Cmax (691 ng/ ml) in površina AUC (1069 ng. h/ ml) precej nižji.
The systemic bioavailability of robenacoxib tablets was 49% without food.
Sistemska biorazpoložljivost tablet robenakoksiba je bila brez hrane 49%.
Distribution Robenacoxib has a relatively small volume of distribution (Vss 190 ml/ kg) and is highly bound to plasma proteins (> 99%).
4 Porazdelitev Robenakoksib ima razmeroma majhno prostornino porazdelitve (Vss 190 ml/ kg) in se zelo dobro veže na plazemske proteine (> 99%).
4 Biotransformation Robenacoxib is extensively metabolised by the liver in cats Apart from one lactam metabolite, the identity of other metabolites is not known in cats
Identiteta presnovkov pri mačkah, razen enega laktamskega, ni znana.
Elimination Robenacoxib is rapidly cleared from blood (CL 0.44 L/ kg/ h) with an elimination t1/ 2 of 1.1 h after intravenous administration.
Izločanje Robenakoksib se iz plazme izloča hitro (CL 0, 44 L/ kg/ h), z razpolovnim časom t1/ 2 1, 1 h po intravenskem dajanju.
After oral administration of tablets, the terminal half-life from blood was 1.7 h.
Po peroralnem vnosu tablet je končni razpolovni čas 1, 7 h.
Robenacoxib persists longer and at higher concentrations at sites of inflammation than in blood.
Na vnetnih mestih ostaja robenakoksib dlje časa in v višjih koncentracijah kot v plazmi.
Robenacoxib is excreted predominantly via the biliary route (∼ 70%) rather than via the kidneys (∼ 30%).
Pretežno se izloča z žolčem (∼70%), v približno 30% pa preko ledvic.
The pharmacokinetics of robenacoxib do not differ between male and female cats.
Farmakokinetika robenakoksiba se med mačkami ženskega in moškega spola ne razlikuje.
Yeast powder Cellulose, microcrystalline Povidone (K-30) Crospovidone Silica, colloidal anhydrous Magnesium stearate
Kvas v prahu Celuloza, mikrokristalna Povidon (K- 30) Krospovidon Silicijev dioksid, koloidni, brezvodni Magnezijev stearat
Cardboard box containing 1, 2 or 10 Alu/ Alu blisters.
Kartonske škatle vsebujejo 1, 2 ali 10 aluminijasto/ aluminijastih pretisnih omotov.
Novartis Animal Health UK Ltd Frimley Business Park Frimley/ Camberley, Surrey, GU16 7SR United Kingdom
Novartis Animal Health UK Ltd Frimley Business Park Frimley/ Camberley, Surrey, GU16 7SR Velika Britanija
16.12.2008
< Datum Odločbe Komisije >
5 mg tablets:
5 mg tablete:
Robenacoxib 5 mg 10 mg tablets:
Robenakoksib 5 mg 10 mg tablete:
Robenacoxib 10 mg 20 mg tablets:
Robenakoksib 10 mg 20 mg tablete:
Robenacoxib 20 mg 40 mg tablets:
Robenakoksib 20 mg 40 mg tablete:
Robenacoxib 40 mg
Robenakoksib 40 mg
Tablet Round, beige to brown tablets with the imprint “ NA ” on one side and the following imprint on the other side:
Tableta Okrogle, bež do rjave barve tablete z vtisnjeno oznako » NA « na eni strani in z naslednjimi vtisnjenimi oznakami na drugi strani:
5 mg tablet:
5 mg tableta:
AK 10 mg tablet:
AK 10 mg tableta:
BE 20 mg tablet:
BE 20 mg tableta:
CD 40 mg tablet:
CD 40 mg tableta:
Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs).
Ne uporabite sočasno s kortikosteroidi ali drugimi nesteroidnimi antirevmatičnimi zdravili (NSAR).
In clinical studies, inadequate response to treatment was seen in 10-15% of the dogs.
V kliničnih študijah je bil neustrezen odgovor na zdravljenje viden pri 10- 15% psov.
The safety of the veterinary medicinal product has not been established in dogs weighing less than 2.5 kg or under 3 months of age.
Posebni previdnostni ukrepi za uporabo pri živalih Varnost zdravila za uporabo v veterinarski medicini ni bila dokazana za pse lažje od 2, 5 kg telesne mase oziroma mlajše od 3 mesecev.
Thereafter it is recommended to continue regular monitoring, e. g. every 3-6 months.
Pri dolgotrajnem zdravljenju je potrebno nadzirati jetrne encime na začetku zdravljenja, npr. po 2, 4 in 8 tednih, v nadaljevanju pa je priporočljiv nadzor vsake 3- 6 mesecev.
Therapy should be discontinued if liver enzyme activities increase markedly or the dog shows clinical signs such as anorexia, apathy or vomiting in combination with elevated liver enzymes.
V primeru vidnega porasta aktivnosti jetrnih encimov oziroma kadar so pri psu vidni klinični znaki anoreksije, apatije ali bruhanja v kombinaciji s povišanimi jetrnimi encimi, je potrebno zdravljenje prekiniti.
Use in dogs with impaired cardiac or renal function or dogs that are dehydrated, hypovolaemic or hypotensive may involve additional risks.
Uporaba pri psih z oslabljenim srčnim ali ledvičnim delovanjem oziroma pri dehidriranih, hipovolemičnih ali hipotenzivnih psih predstavlja dodatno tveganje.
Use this product under strict veterinary monitoring in dogs with a risk of gastrointestinal ulcers, or if the dog previously displayed intolerance to other NSAIDs.
Pri psih s tveganjem za nastanek razjed v prebavilih oziroma z znano preobčutljivostjo na druge NSAR uporabite to zdravilo pod strogim veterinarskim nadzorom.
In small children, accidental ingestion increases the risk for NSAID adverse effects.
Nenamerno zaužitje pri majhnih otrocih poveča tveganje za neželene učinke NSAR.
For pregnant women, particularly near term pregnant women, prolonged dermal exposure increases the risk of premature closure of the ductus arteriosus in the foetus.
Dolgotrajnejše izpostavljanje kože pri nosečnicah, zlasti blizu porodnega termina, poveča tveganje za predčasno zaprtje duktusa arteriozusa pri plodu.
Gastrointestinal adverse events were reported very commonly, but most cases were mild and recovered without treatment.
Zelo pogosto so bili opisani neželeni učinki na prebavilih, ki pa so bili v večini primerov blagi in so se popravili brez zdravljenja.
In dogs treated up to 2 weeks no increases in liver enzyme activities were observed.
Pri psih zdravljenih do 2 tednov ni bilo opaziti porasta aktivnosti jetrnih encimov.
However, with long-term treatment, increases in liver enzyme activities were common.
Vendar pa je bila pogosto povišana pri dolgotrajnem zdravljenju.
In most cases there were no clinical signs and the liver enzyme activities either stabilised or decreased with continued treatment.
V večini primerov ni bilo prisotnih kliničnih znakov in z nadaljevanjem zdravljenja se je aktivnost jetrnih encimov stabilizirala ali zmanjšala.
Increases in liver enzyme activities associated with clinical signs of anorexia, apathy or vomiting were uncommon.
V povezavi s kliničnimi znaki anoreksije, apatije ali bruhanja je bila aktivnost jetrnih encimov manj pogosto povečana.
Do not use in pregnant or lactating dogs because the safety of robenacoxib has not been established during pregnancy and lactation or in dogs used for breeding.
Ne uporabite pri psicah v obdobju brejosti ali laktacije oziroma pri psicah, namenjenih za razplod, ker varnost robenakoksiba pri teh živalih ni bila ugotovljena.
8 4.8 Interaction with other medicinal products and other forms of interaction
8 4. 8 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Onsior must not be administered in conjunction with other NSAIDs.
Onsior se ne sme uporabljati skupaj z drugimi NSAR.
Pre-treatment with other anti- inflammatory medicines may result in additional or increased adverse effects and accordingly a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior.
Predhodno zdravljenje z drugimi antirevmatičnimi zdravili lahko povzroči dodatne ali povečane neželene učinke, zato je potrebno pred pričetkom zdravljenja z Onsiorjem opazovati obdobje brez zdravljenja s takšnimi snovmi vsaj 24 ur.
Concurrent administration of potentially nephrotoxic medicines should be avoided as there might be an increased risk of renal toxicity.
Izogibajte se sočasni uporabi potencialno nefrotoksičnih zdravil, ker obstaja povečano tveganje toksičnega vpliva na ledvice.
Onsior tablets are flavoured and are taken voluntarily by most dogs.
Onsior tablete so aromatizirane in jih večina psov poje prostovoljno.
The tablets should not be divided or broken.
Tablete ne smejo biti deljene ali prelomljene.
The recommended dose of robenacoxib is 1 mg/ kg body weight with a range 1-2 mg/ kg.
Priporočen odmerek robenakoksiba je 1 mg/ kg telesne mase v območju 1- 2 mg/ kg.
Number of tablets Body weight (kg)
Število tablet Telesna masa
2.5 to < 5 5 to < 10 10 to < 20 20 to < 40 40 to 80
do < 5
1 tablet 2 tablets
1 tableta 2 tableti
A clinical response is normally seen within a week.
Klinični odziv je normalno viden v enem tednu.